Ignacio Faus
Net worth: 12 890 $ as of 2026-09-29
Net worth: 12 890 $ as of 2026-09-29
Dr. Ignacio Faus is a Deputy Chief Executive Officer & Director at NFL Biosciences SAS and an Advisor at DRI Healthcare.
He is on the Board of Directors at NFL Biosciences SAS. Dr. Faus was previously employed as a Chief Executive Officer by Mologen AG, a Chief Executive Officer by Palau Pharma SA, a Manager-Business Development by J.
Uriach y Cia SA, a Chief Executive Officer & Director by Genmedica Therapeutics SL, and an Executive Director by Sage Healthcare Ltd. He received his MBA from Kellogg School of Management and a doctorate degree from Indiana University.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
DRI Healthcare Trust
DRI Healthcare Trust Investment Trusts/Mutual FundsMiscellaneous Operates as a royalty trust 0% | 2025-11-12 | 1,000 ( 0% ) | 12 890 $ | 2026-09-29 |
| Companies | Position | Start |
|---|---|---|
| NFL BIOSCIENCES | Director/Board Member | 2024-10-16 |
DRI Healthcare
DRI Healthcare Investment ManagersFinance DRI Healthcare invests in royalty interests in leading pharmaceutical and biotechnology companies, research institutions, universities and inventors. | Consultant / Advisor | - |
| Companies | Position | End |
|---|---|---|
| MOLOGEN AG | Chief Executive Officer | 2019-03-30 |
Palau Pharma SA
Palau Pharma SA BiotechnologyHealth Technology Provides research and development services to the pharmaceutical sector | Chief Executive Officer | 2012-12-31 |
Noucor Health SA
Noucor Health SA Miscellaneous Commercial ServicesCommercial Services Engages in research, development and manufacturing of medicines & food supplements | Corporate Officer/Principal | 2006-10-31 |
Sage Healthcare Ltd.
Sage Healthcare Ltd. Miscellaneous Commercial ServicesCommercial Services Provides management consulting services to the healthcare industry | Director/Board Member | - |
Genmedica Therapeutics SL
Genmedica Therapeutics SL BiotechnologyHealth Technology Engages in the research and development of treatments for metabolic disorders | Chief Executive Officer | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 9 |
|---|---|
DRI Healthcare
DRI Healthcare Investment ManagersFinance DRI Healthcare invests in royalty interests in leading pharmaceutical and biotechnology companies, research institutions, universities and inventors. | Finance |
MOLOGEN AG
MOLOGEN AG Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops immunotherapies for the treatment of infectious diseases | Health Technology |
Indiana University
Indiana University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Noucor Health SA
Noucor Health SA Miscellaneous Commercial ServicesCommercial Services Engages in research, development and manufacturing of medicines & food supplements | Commercial Services |
Genmedica Therapeutics SL
Genmedica Therapeutics SL BiotechnologyHealth Technology Engages in the research and development of treatments for metabolic disorders | Health Technology |
Palau Pharma SA
Palau Pharma SA BiotechnologyHealth Technology Provides research and development services to the pharmaceutical sector | Health Technology |
Sage Healthcare Ltd.
Sage Healthcare Ltd. Miscellaneous Commercial ServicesCommercial Services Provides management consulting services to the healthcare industry | Commercial Services |
Kellogg School of Management
Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
NFL Biosciences SAS
NFL Biosciences SAS BiotechnologyHealth Technology Operates as a biotechnology company that develops botanical treatments for addictions | Health Technology |
Select your edition
All financial news and data tailored to specific country editions